Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Publication/Presentation Date
1-1-2016
Abstract
Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
Volume
16
Issue
9
First Page
755
Last Page
764
ISSN
1873-5576
Published In/Presented At
Selvan, S. R., Dowling, J. P., Kelly, W. K., & Lin, J. (2016). Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies. Current cancer drug targets, 16(9), 755–764. https://doi.org/10.2174/1568009615666151030102250
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
26517538
Department(s)
Administration and Leadership
Document Type
Article